AI has reset the board on knowledge work. We are in a land grab to reinvent every intelligence-driven business.
The Discovery Tsunami
AI is accelerating scientific discovery at an unprecedented rate. AI-powered drug discovery, novel modalities, target identification, and drug repurposing are generating a 10-100x increase in new drug candidates. The faucet is wide open.
But downstream, the pipe is clogged. Clinical development remains too slow (5-10+ year timelines), too expensive ($2B+ per drug), and plagued by low probability of success (90% failure rate). Drug approvals have been stagnant for 80+ years.
The bottleneck is not a dearth of biology. It is a dearth of conviction and quality assets. The missing ingredient is the ability to rapidly identify unmet needs, design best-in-class drug profiles, and execute clinical development with radical efficiency.
Fast Takeoff
Frontier AI capabilities are accelerating on every dimension. The model slope is not slowing down. Recursive self-improvement is beginning. We are likely 6-12 months from recursive self-improving organizational systems.
In this world, legacy organizational structure and headcount are a liability. Incumbent assets, people, and infrastructure are actually an impediment to moving fast — creating a unique moment-in-time opportunity to build a new, massive business.
Specialized domain knowledge, integration, and human judgment remain defensible for 12-36 months. The window is open, and it won't stay open forever.
The Danger Zone
In a fast takeoff, middle-layer value erodes. There is nothing durable in building narrow software tooling that will be commoditized. Only four categories are investible in a world of accelerating AI:
AI Labs
Building raw frontier intelligence. The foundation layer.
Proprietary Data
Unique, defensible datasets that models can't replicate.
Hardware / Atoms
Physical infrastructure and real-world assets. Can't be software-eaten.
Full-Stack, IP-Protected Assets
Terminal assets with regulatory moats — FDA approvals, patents, exclusivity.
Fibonacci converts AI into the most defensible asset class: FDA-approved, patent-protected therapies. The AI is the means of production, but the product — an approved drug — lives in a completely different defensibility regime.
The Fibonacci Thesis
Fibonacci Bio is built on a contrarian thesis: the hardest problems in pharma today are not biological; they are about conviction, speed, and operational excellence.
We are building a full-stack AI-native drug hunting and development company. The Asset Foundry identifies and designs best-in-class drug profiles. The Refinery executes clinical development with radical efficiency. Together, they can deliver 6 drugs for the cost of one conventional program.
We don't just want to make drugs faster. We want to 10x the number of drugs that reach patients — expanding the addressable pipeline to diseases the industry has ignored because the economics didn't work under the old model.